Chinese Journal of Cancerindexed by SCI
《癌症》杂志
BMC

About the cover
About the cover

Jul. 2015; Volume 34 Issue 7


In July 2000, the US FDA approved tamoxifen to reduce the risk of invasive breast cancer in women with ductal carcinoma in situ (DCIS) following breast surgery and radiation. Tamoxifen is the first medication to be approved for DCIS, which accounts for nearly 20 percent of all newly diagnosed breast cancer cases. From The Coming Cancer Breakthroughs.


Perspective
Parallel phase 1 clinical trials in the US and in China: accelerating the test of avitinib in lung cancer as a novel inhibitor selectively targeting mutated EGFR and overcoming T790M-induced resistance
Xiao Xu
[ Abstract  1343]  [ PDF Full-text  1498]   [ HTML Full-text  896]    Epub: 2015-7-8  doi: 10.1186/s40880-015-0029-3
Original Article
Insight into early-phase trials for lung cancer in the United States
Jin-Ji Yang and Yi-Long Wu
[ Abstract  914]  [ PDF Full-text  1011]   [ HTML Full-text  929]    Epub: 2015-7-11  doi: 10.1186/s40880-015-0027-5
Review
Predictive biomarkers in precision medicine and drug development against lung cancer
Bingliang Fang, Reza J Mehran, John V Heymach and Stephen G Swisher
[ Abstract  940]  [ PDF Full-text  1130]   [ HTML Full-text  899]    Epub: 2015-7-3  doi: 10.1186/s40880-015-0028-4
Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what’s new and what’s enough
Fei Zhou and Cai-Cun Zhou
[ Abstract  873]  [ PDF Full-text  931]   [ HTML Full-text  915]    Epub: 2015-7-18  doi: 10.1186/s40880-015-0036-4
Global efforts in conquering lung cancer in China
Li Yan and Li Xu
[ Abstract  837]  [ PDF Full-text  931]   [ HTML Full-text  807]    Epub: 2015-7-28  doi: 10.1186/s40880-015-0034-6
Letter to the Editor
Early-Phase Oncology Research Training (EFFORT) program: a Hengrui-USCACA joint scholarship
Li Yan and Li Xu
[ Abstract  1246]  [ PDF Full-text  1035]   [ HTML Full-text  1014]    Epub: 2015-7-8  doi: 10.1186/s40880-015-0035-5




CJC Wechat 微信公众号

CJC触屏版


 

Editorial Manager


CJC adopts Editorial Manager to manage its submissions from Dec.18, 2014
 

 

Reference style for  

 EndNote,
 Reference Manager



Editorial Manager


 

Year:

 

Month:

Advanced search

Subscription


CJC is now published by BioMed Central

© Chinese Journal of Cancer

Sun Yat-sen University Cancer Center

651 Dongfeng Road East, Guangzhou 510060, P. R. China